Clinical trials showed that NeuroAiD™ helps in stroke recovery
NeuroAiD™ doubles chances of achieving independence.
Trials on 605 subjects, recruited within 2 weeks to 6 months after an ischemic stroke, demonstrated that patients on NeuroAiD™ have 2.4 more changes of achieving independence* after 1 month of treatment (p=0.007). Independence for a stroke victim is the ability to walk, think and live decently after his recovery.
*Independence is defined as being able to takecare of oneself and speak freely.
NeuroAiD™ improves activities of daily living.
A double-blind, placebo-control clinical trial on 80 subjects showed better improvement in ability to perform activities of daily living at 3 months among NeuroAiDTM treated patients as compared to controls (Barthel Index improvement of 36 vs 29 points; p<0.001).
Improving Motor Recovery
A study of 150 subjects recruited between 1 week and 3 months after stroke onset received 3 months of treatment. Motor recovery was assessed by Fugl-Meyer motor assessment scale (maximum score 100 points) every month for 3 months. This study showed that the motor recovery of patients on NeuroAiD™ was significantly much more than patients on placebo, and this difference was seen as early as 4 weeks from start of treatment and persists up to 3 months.
Trials on 605 subjects recruited within 2 weeks and 6 months post ischemic stroke showed statistically significant improvement in upper limb (p=0.006) and distal lower limb paralysis* (p=0.02) after 1 month of treatment with NeuroAiD™ compared to the control group.
*The recovery of paralysis was measured on a normalized 0-5 points scale before and after treatment.
Effects on other brain functions
NeuroAiD™ supports recovery of visual deficits
A study of 40 patients with pure homonymous hemianopsia from ischemic stroke, recruited within one week of onset and treated with either NeuroAiD™ or piracetam for 3 months, showed that patients on NeuroAiD™ gained back more of their visual field at 3 months compared to control.
A case series published in European Neurology reported 10 cases of patients, from Mount Alvernia Hospital in Singapore, who received 2 to 3 months treatment of NeuroAiD™ after a stroke. Treatment was initiated between one week and six months post-stroke and given as an add-on medication.
The cases were a mixture of anterior and posterior circulation infarction with motor, sensory, balance,vision, and/or speech deficits.
All cases reported improvements:
- 6 cases of full recovery
- 2 cases of good recovery
- 1 case of moderate recovery
- 1 case of only minor recovery
Significant improvements were recorded in speech and visual functions, aside from motor and balance. Remarkably, three patients who started NeuroAiD™ treatment at a later stage of stroke recovery (i.e. 1 to 6 months after the stroke and recovery has reached a plateau) experienced significant recovery.
NeuroAiD™ should be taken in addition to prevention drugs that are commonly prescribed by your doctor; these typically include antiplatelet, antihypertensive, and cholesterol-lowering drugs, among others.
To date, no drug interactions with NeuroAiD™ have been reported. Systematic clinical trials have shown that NeuroAiD™ does not have any interaction with aspirin. Patients taking NeuroAiD™ with anticoagulants have reportedly shown no impact on their INR (International Normalized Ratio). Nevertheless, as with any other new drug combined with anticoagulants, it is recommended that you ask your physician to monitor your INR when you initiate NeuroAiD™ stroke treatment, as should be done for any change in your prescription medicines.
We have been asking our customers to share with us the list of concomitant medications they have been taking with NeuroAiD™. This list is constantly updated. Do not hesitate to inquire about any specific medication by contacting our customer care Team
Published clinical trials have confirmed that NeuroAiD™ has no effect on thinning the blood or on liver or renal functions; similarly, NeuroAiD™ has no effect on blood pressure.
The initial clinical trials on NeuroAiD™ reported only rare cases of nausea and vomiting for patients taking NeuroAiD™ .In most cases, doctors have advised patients to halve the dose of NeuroAiD™ during the first week and progressively increase it.
Moleac’s pharmacovigilance database records only rare and minor side effects: very rare cases of mild headaches, nausea or vomiting, diarrhea and dizziness, and rare cases of dry throat/increased thirst after several months of NeuroAiD™ stroke treatment, and therefore a need to drink more water.
NeuroAiD™ has been manufactured in the same facility for the past ten years under the recognized principles of current Good Manufacturing Practice (GMP).
The GMP standards are applied to procedures in manufacturing dietary supplements, including approval of raw materials, production and process controls, laboratory testing, and product packaging, labeling, and distribution. These processes are regularly audited by independent health authorities.
The ingredients are carefully selected in compliance with the Chinese Pharmacopoeia’s standards. Every batch of NeuroAiD™ is analyzed thoroughly by third-party independent laboratories to confirm compliance with international standards, ensuring utmost safety for patients.